Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors

Trial Profile

Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Theliatinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 29 Sep 2017 Results presented in a Chi-Med media release.
    • 29 Sep 2017 According to a Chi-Med media release, results were presented at the Chinese Society of Clinical Oncology (CSCO) 2017.
    • 13 Jan 2017 Planned number of patients changed from 18 to 66.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top